{"id":"0e8f89f20580","type":"article","url":"https://hartvaat.nl/2022/06/01/sglt2-remmers-bij-hartfalen-geupdatete-meta-analyse-bevestigt-breed-voordeel/","title":"SGLT2-remmers bij hartfalen: geüpdatete meta-analyse bevestigt breed voordeel","title_en":"Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","canagliflozine","cardiorenal-behandelstrategie","dapagliflozine","empagliflozine","fidelity","sglt2-remmers"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13905","source_url":"https://doi.org/10.1002/ehf2.13905","authors":["Yang Cao","Pengxiao Li","Yi Li","Yaling Han"],"significance":8,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This updated meta-analysis confirmed that SGLT2 inhibitors reduce cardiovascular death and heart failure hospitalization in both HFrEF and HFpEF, with the magnitude of benefit consistent across the ejection fraction spectrum regardless of diabetes status.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Geactualiseerde meta-analyse bevestigde dat SGLT2-remmers het risico op cardiovasculaire sterfte en hartfalenhospitalisatie verlagen bij zowel HFrEF als HFpEF. Het voordeel was consistent ongeacht de aanwezigheid van diabetes. SGLT2-remmers worden hiermee een universele hartfalenbehandeling.","abstract_original":"AIMS: We aimed to examine efficacy and safety outcomes of sodium-glucose cotransporter-2 inhibitor (SGLT2i) for the treatment of heart failure (HF), especially in patients with heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: PubMed, Web of Science, and Cochrane Library were searched to identify randomized controlled trials comparing SGLT2i vs. placebo in HF patients. A total of 10 studies with 23 852 HF patients were eventually included. Compared with placebo, SGLT2i is associated with a lower incidence of composite of first hospitalization for heart failure (HHF) or cardiovascular death (CV death) [hazard ratio (HR) = 0.76 95% confidence interval (CI) = 0.71-0.81], which is consistent regardless of the diabetes status, type of gliflozines used, and follow-up duration. SGLT2i can reduce the risk of total HHF or CV death (HR = 0.74, 95%CI = 0.68-0.81), first HHF (HR = 0.69, 95%CI = 0.64-0.75), CV death (HR = 0.88, 95%CI = 0.80-0.96), any death (HR = 0.90, 95%CI = 0.83-0.97), and any serious events (HR = 0.90, 95%CI = 0.87-0.93) in HF patients, at the cost of increased risk of urinary tract infections (risk ratio = 1.17, 95%CI = 1.03-1.33). In HFpEF patients, SGLT2i is associated with a significant reduction of composite of first HHF or CV death (HR = 0.81, 95%CI = 0.73-0.91), first HHF (HR = 0.71, 95%CI = 0.62-0.82), and total HHF or CV death (HR = 0.61, 95%CI = 0.43-0.86). CONCLUSIONS: Sodium-glucose cotransporter-2 inhibitor contributed to better efficacy outcomes in overall HF patients and showed an inspiring breakthrough in the treatment of HFpEF."}